MX2009003222A - Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. - Google Patents
Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.Info
- Publication number
- MX2009003222A MX2009003222A MX2009003222A MX2009003222A MX2009003222A MX 2009003222 A MX2009003222 A MX 2009003222A MX 2009003222 A MX2009003222 A MX 2009003222A MX 2009003222 A MX2009003222 A MX 2009003222A MX 2009003222 A MX2009003222 A MX 2009003222A
- Authority
- MX
- Mexico
- Prior art keywords
- hdl
- pyridinecarboxamide
- raising agents
- cholesterol raising
- pyrazinecarboxamide derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
La presente invención se refiere al uso de compuestos de la fórmula (ver fórmula (I)) en donde A, G, R1 a R8 y R17 son como se definió en la descripción, en la preparación de medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden ser tratadas con agentes elevadores de colesterol HDL, tales como enfermedad vascular periférica, dislipidemia, hiperbetalipoproteinemia, hipoalfalipoproteinemia, hipercolesterolemia, hipertrigliceridemia, hipercolesterolemia familiar, trastornos cardiovasculares, angina, isquemia, isquemia cardiaca, apoplejía, infarto de miocardio, lesión de reperfusión, restenosis angioplástica, hipertensión, y complicaciones vasculares de diabetes, obesidad o endotoxemia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06121755 | 2006-10-04 | ||
PCT/EP2007/060094 WO2008040651A1 (en) | 2006-10-04 | 2007-09-24 | 3-pyridinecarboxamide and 2-pyrazinecarboxamide derivatives as hdl-cholesterol raising agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009003222A true MX2009003222A (es) | 2009-04-06 |
Family
ID=38740266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009003222A MX2009003222A (es) | 2006-10-04 | 2007-09-24 | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. |
Country Status (14)
Country | Link |
---|---|
US (3) | US20080085906A1 (es) |
EP (2) | EP2074096B1 (es) |
JP (1) | JP2010505789A (es) |
KR (1) | KR101107896B1 (es) |
CN (1) | CN101522626A (es) |
AU (1) | AU2007304365A1 (es) |
BR (1) | BRPI0717845A2 (es) |
CA (1) | CA2664119A1 (es) |
IL (1) | IL197577A0 (es) |
MX (1) | MX2009003222A (es) |
NO (1) | NO20091045L (es) |
RU (1) | RU2454405C2 (es) |
WO (1) | WO2008040651A1 (es) |
ZA (1) | ZA200902353B (es) |
Families Citing this family (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20070087096A (ko) | 2004-12-14 | 2007-08-27 | 아스트라제네카 아베 | Dgat 억제제로서의 옥사디아졸 유도체 |
EP1966221A1 (en) | 2005-12-22 | 2008-09-10 | AstraZeneca AB | Pyrimido- [4, 5-]-oxazines for use as dgat inhibitors |
CA2651710A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Substituted 5-phenylamino-1,3,4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase |
WO2007138304A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors |
US7781593B2 (en) * | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
CA2707660A1 (en) | 2007-12-20 | 2009-07-02 | Astrazeneca Ab | Carbamoyl compounds as dgat1 inhibitors 190 |
US8088920B2 (en) * | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
US7897621B2 (en) | 2008-03-31 | 2011-03-01 | Hoffmann-La Roche Inc. | 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents |
CN102264721B (zh) | 2008-11-10 | 2015-12-09 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的化合物 |
KR101745331B1 (ko) | 2008-12-19 | 2017-06-09 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 키나제의 억제제로서 유용한 피라진 유도체 |
US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
JP2012530122A (ja) | 2009-06-19 | 2012-11-29 | アストラゼネカ アクチボラグ | Dgat1の阻害剤としてのピラジンカルボキシアミド |
UA107088C2 (xx) | 2009-09-11 | 2014-11-25 | 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину | |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
NZ603477A (en) | 2010-05-12 | 2014-09-26 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
WO2011143419A1 (en) * | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
US9334244B2 (en) | 2010-05-12 | 2016-05-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2569284B1 (en) | 2010-05-12 | 2015-07-08 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
AU2011270807A1 (en) | 2010-06-23 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase |
WO2012031817A1 (en) | 2010-09-09 | 2012-03-15 | F. Hoffmann-La Roche Ag | Determination of abca1 protein levels in cells |
US8410107B2 (en) * | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
US20120101282A1 (en) * | 2010-10-22 | 2012-04-26 | Pascal Dott | Process for the preparation of nicotinamide derivatives |
US8669254B2 (en) | 2010-12-15 | 2014-03-11 | Hoffman-La Roche Inc. | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents |
KR20140027974A (ko) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Tra 키나제의 억제제로서 유용한 아미노피라진 화합물 |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
US9309250B2 (en) | 2011-06-22 | 2016-04-12 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2013037704A1 (en) * | 2011-09-12 | 2013-03-21 | F. Hoffmann-La Roche Ag | N-(5-cycloalkyl- or 5-heterocyclyl-)-pyridin-3-yl carboxamides |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
CN103796997A (zh) * | 2011-09-12 | 2014-05-14 | 霍夫曼-拉罗奇有限公司 | 5-环烷基-或5-杂环基-烟酰胺 |
MX2014001860A (es) | 2011-09-12 | 2014-05-30 | Hoffmann La Roche | Hidrazidas del acido 3-piridin carboxilico como agentes elevadores del colesterol de lipoproteina de alta densidad (hdl). |
WO2013049719A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
ES2899880T3 (es) | 2011-09-30 | 2022-03-15 | Vertex Pharma | Tratamiento de cáncer de páncreas y cáncer de pulmón de células no pequeñas con inhibidores de ATR |
AU2012315611A1 (en) | 2011-09-30 | 2014-04-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
HUE046429T2 (hu) | 2011-09-30 | 2020-03-30 | Vertex Pharma | ATR kináz inhibítoraként használható vegyületek elõállítására szolgáló eljárás |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9403808B2 (en) * | 2011-10-28 | 2016-08-02 | Hoffmann-La Roche Inc. | Pyrazine derivatives |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776422A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
IN2014KN02410A (es) | 2012-04-05 | 2015-05-01 | Vertex Pharma | |
CA2880477A1 (en) | 2012-08-23 | 2014-02-27 | F. Hoffmann-La Roche Ag | Novel phenyl-pyridine/pyrazine amides for the treatment of cancer |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP3418281B1 (en) | 2012-12-07 | 2020-09-30 | Vertex Pharmaceuticals Inc. | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases |
RU2668073C2 (ru) | 2013-03-14 | 2018-09-26 | Дарт Нейросайенс (Кайман) Лтд. | Замещенные пиридиновые и пиразиновые соединения в качестве ингибиторов pde4 |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
MX370390B (es) | 2013-12-06 | 2019-12-11 | Vertex Pharma | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. |
CN110590787A (zh) | 2014-06-05 | 2019-12-20 | 沃泰克斯药物股份有限公司 | Atr激酶抑制剂的制备方法及其不同的固体形式 |
JP6936007B2 (ja) | 2014-06-17 | 2021-09-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法 |
CN115925679A (zh) * | 2014-12-24 | 2023-04-07 | 株式会社Lg化学 | 作为gpr120激动剂的联芳基衍生物 |
KR20180052635A (ko) | 2015-09-18 | 2018-05-18 | 가켄 세이야쿠 가부시키가이샤 | 바이아릴 유도체 및 이를 포함하는 약제 |
MX2018003657A (es) | 2015-09-30 | 2018-04-30 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan el adn e inhibidores de proteina relacionada con ataxia telangiectasia y rad3 (atr). |
JP2021501210A (ja) * | 2017-10-30 | 2021-01-14 | モントリオール ハート インスティテュート | 血漿コレステロールの上昇を処置する方法 |
PL237374B1 (pl) * | 2017-11-10 | 2021-04-06 | Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia | Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie |
WO2024003259A1 (en) * | 2022-06-30 | 2024-01-04 | Bayer Aktiengesellschaft | Tead inhibitors |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104330D0 (sv) * | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
CA2527033A1 (en) | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5,6-diaryl-pyrazine derivatives as cb1 modulators |
ES2326280T3 (es) | 2005-04-06 | 2009-10-06 | F. Hoffmann-La Roche Ag | Derivados de piridin-3-carboxamida como agonistas inversos de cb1. |
WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
US7629346B2 (en) | 2006-06-19 | 2009-12-08 | Hoffmann-La Roche Inc. | Pyrazinecarboxamide derivatives as CB1 antagonists |
US7781593B2 (en) * | 2006-09-14 | 2010-08-24 | Hoffmann-La Roche Inc. | 5-phenyl-nicotinamide derivatives |
MX2009003316A (es) * | 2006-10-04 | 2009-04-09 | Hoffmann La Roche | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. |
US8088920B2 (en) | 2008-03-31 | 2012-01-03 | Hoffmann-La Roche Inc. | 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents |
-
2007
- 2007-09-24 WO PCT/EP2007/060094 patent/WO2008040651A1/en active Application Filing
- 2007-09-24 BR BRPI0717845-0A patent/BRPI0717845A2/pt not_active IP Right Cessation
- 2007-09-24 RU RU2009116670/04A patent/RU2454405C2/ru not_active IP Right Cessation
- 2007-09-24 EP EP07820501A patent/EP2074096B1/en not_active Not-in-force
- 2007-09-24 AU AU2007304365A patent/AU2007304365A1/en not_active Abandoned
- 2007-09-24 JP JP2009530843A patent/JP2010505789A/ja active Pending
- 2007-09-24 KR KR1020097009023A patent/KR101107896B1/ko not_active IP Right Cessation
- 2007-09-24 CA CA002664119A patent/CA2664119A1/en not_active Abandoned
- 2007-09-24 CN CNA2007800369086A patent/CN101522626A/zh active Pending
- 2007-09-24 EP EP12153000A patent/EP2450350A1/en not_active Withdrawn
- 2007-09-24 MX MX2009003222A patent/MX2009003222A/es active IP Right Grant
- 2007-09-27 US US11/904,425 patent/US20080085906A1/en not_active Abandoned
-
2009
- 2009-02-06 US US12/366,692 patent/US7812028B2/en not_active Expired - Fee Related
- 2009-03-10 NO NO20091045A patent/NO20091045L/no not_active Application Discontinuation
- 2009-03-12 IL IL197577A patent/IL197577A0/en unknown
- 2009-04-03 ZA ZA200902353A patent/ZA200902353B/xx unknown
-
2010
- 2010-06-29 US US12/825,374 patent/US8188093B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NO20091045L (no) | 2009-03-31 |
BRPI0717845A2 (pt) | 2015-06-16 |
EP2074096B1 (en) | 2012-06-27 |
US20100267745A1 (en) | 2010-10-21 |
IL197577A0 (en) | 2009-12-24 |
JP2010505789A (ja) | 2010-02-25 |
US20080085906A1 (en) | 2008-04-10 |
WO2008040651A1 (en) | 2008-04-10 |
US20090143409A1 (en) | 2009-06-04 |
US8188093B2 (en) | 2012-05-29 |
AU2007304365A1 (en) | 2008-04-10 |
EP2074096A1 (en) | 2009-07-01 |
CA2664119A1 (en) | 2008-04-10 |
KR101107896B1 (ko) | 2012-01-25 |
KR20090075852A (ko) | 2009-07-09 |
ZA200902353B (en) | 2010-04-28 |
RU2454405C2 (ru) | 2012-06-27 |
US7812028B2 (en) | 2010-10-12 |
CN101522626A (zh) | 2009-09-02 |
EP2450350A1 (en) | 2012-05-09 |
RU2009116670A (ru) | 2010-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009003222A (es) | Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad. | |
NO20056056L (no) | N-actyl nitrogenheterocykler som ligander av peroksisom-proliferatoraktiverte reseptorer | |
CY1109925T1 (el) | Η χρηση πυριδυλ αμιδιων ως παρεμποδιστων της αγγειογενεσης | |
WO2007065662A3 (en) | Trisubstituted quinazolinone derivatives as vanilloid antagonists | |
IN2012DN03043A (es) | ||
WO2010057101A3 (en) | Compounds useful as hiv blockers | |
CL2011002604A1 (es) | Compuestos derivados de n-(cianometil)-4-(sulfonil)pirrolidina-2-carboxamida, inhibidores de catepsina s o l; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, aterosclerosis, aneurismo aortico abdominal, enfermedades arteriales periferica o la nefropatia diabetica. | |
TNSN07007A1 (en) | 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha -7- nachr ligands for the treatment of cns diseases | |
EA201391786A1 (ru) | Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
RU2013120312A (ru) | Имидазохинолины и производные пиримидина в качестве потенциальных модуляторов vegf-стимулируемых ангиогенных процессов | |
TW200800997A (en) | Chemical compounds | |
EA201391670A1 (ru) | 1,3-оксазины в качестве ингибиторов bace1 и/или bace2 | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
TN2013000285A1 (en) | Novel heterocyclic derivatives and their use in the treatment of neurological disorders | |
TW200726767A (en) | Chemical compounds 2 | |
WO2006067224A3 (en) | Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists | |
WO2010077101A3 (ko) | 신규한 티아졸리딘디온 유도체 및 그의 용도 | |
EA201001585A1 (ru) | Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк) | |
WO2007041112A3 (en) | Dihydro-[1h]-quinolin-2-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes | |
EA200801775A1 (ru) | Пиридин-4-илметиламиды для борьбы с вредителями | |
BR112014001880A2 (pt) | derivados de carboxamida e ureia contendo pirazol heteroaromáticos substituídos como ligantes de receptor vaniloide | |
TW200714603A (en) | Acylaminobicyclic heteroaromatic compounds and uses thereof | |
MX2013014194A (es) | 1,3-tiazepinas fusionadas a ciclopropilo como inhibidores de beta-secretasa 1 (bace) y/o beta-secretasa 2 (bace 2). | |
NZ597857A (en) | Method and composition for treating mucosal disorders | |
WO2007041076A3 (en) | 1,2,3,5-tetrahydro-cyclopental[c]quinolin-4-one derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |